Corrigendum: Comparison of Efficacy and Safety between First and Second Generation Drug-eluting Stents in Patients with Stable Coronary Artery Disease: A Single-center Retrospective Study

In the article “Comparison of Efficacy and Safety between First and Second Generation Drug-eluting Stents in Patients with Stable Coronary Artery Disease: A Single-center Retrospective Study” which appeared in vol.130, issue 14, page 1655 of Chinese Medical Journal,^[1] “G1–DES included sirolimus–eluting stents (Partner, Lepu Medical, China; Firebird, MicroPort Medical, China), paclitaxel–eluting stents (Taxus and Taxus Liberté, Boston Scientific, USA). G2–DES included zotarolimus–eluting stents (Endeavor and Endeavor Resolute, Medtronic Vascular, USA), everolimus–eluting stents (Xience V and Xience Prime, Abbott Vascular, USA; Promus and Promus Element, Boston Scientific, USA), and domestic sirolimus–eluting stents (Firebird2, MicroPort Medical, China).” should be corrected as “G1–DES included sirolimus–eluting stents (Partner, Lepu Medical, China; Firebird and Firebird2, MicroPort Medical, China), paclitaxel–eluting stents (Taxus and Taxus Liberté, Boston Scientific, USA). G2–DES included zotarolimus–eluting stents (Endeavor and Endeavor Resolute, Medtronic Vascular, USA), everolimus–eluting stents (Xience V and Xience Prime, Abbott Vascular, USA; Promus and Promus Element, Boston Scientific, USA).” The original results and conclusions are not affected.